NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 5 pharmaceutical companies such as AM REGENT, FRESENIUS KABI USA, SUN PHARM and others. It is marketed under 3 brand names, including SELENIOUS ACID, TRALEMENT, MULTRYS. Available in 6 different strengths, such as EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML), EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML), EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) and others, and administered through 1 route including SOLUTION;INTRAVENOUS.
API availability: Loading API feasibility...
Licensing: 5 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"35847","ingredient":"CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE","trade_name":"MULTRYS","family_id":"65e1bb82a52048e1af93","publication_number":"US11786548B2","cleaned_patent_number":"11786548","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-07-01","publication_date":"2023-10-17","legal_status":"Patented case"} | US11786548B2 Formulation | 17 Oct, 2023 | Patented case | 01 Jul, 2041 | |
| {"application_id":"121548","ingredient":"CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE","trade_name":"MULTRYS","family_id":"65e1bb82a52048e1af93","publication_number":"US11975022B2","cleaned_patent_number":"11975022","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-07-01","publication_date":"2024-05-07","legal_status":"Patented case"} | US11975022B2 | 07 May, 2024 | Patented case | 01 Jul, 2041 | |
| {"application_id":"113828","ingredient":"CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE","trade_name":"MULTRYS","family_id":"65e1bb82a52048e1af93","publication_number":"US11998565B2","cleaned_patent_number":"11998565","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-07-01","publication_date":"2024-06-04","legal_status":"Granted"} | US11998565B2 Formulation | 04 Jun, 2024 | Granted | 01 Jul, 2041 | |
| {"application_id":"122951","ingredient":"CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE","trade_name":"MULTRYS","family_id":"65e1bb82a52048e1af93","publication_number":"","cleaned_patent_number":"12150956","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-07-01","publication_date":"2024-11-26","legal_status":"Patented case"} | US12150956B2 | 26 Nov, 2024 | Patented case | 01 Jul, 2041 | |
| {"application_id":"123283","ingredient":"CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE","trade_name":"MULTRYS","family_id":"65e1bb82a52048e1af93","publication_number":"","cleaned_patent_number":"12150957","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-07-01","publication_date":"2024-11-26","legal_status":"Patented case"} | US12150957B2 | 26 Nov, 2024 | Patented case | 01 Jul, 2041 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Selenious Acid
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.